Navigation Links
Study unmasks how ovarian tumors evade immune system
Date:12/1/2008

Scientists at Johns Hopkins have determined how the characteristic shedding of fatty substances, or lipids, by ovarian tumors allows the cancer to evade the body's immune system, leaving the disease to spread unchecked. Ovarian cancer is considered to be one of the most aggressive malignancies, killing more than 70 percent of diagnosed women within five years, including an estimated 15,000 this year.

In a two-year series of lab experiments, a team of researchers from the Johns Hopkins University School of Medicine and its Sidney Kimmel Comprehensive Cancer Center showed that fluid secretions from tumors, called ascites, which contain lipids and collect in the space surrounding cancerous ovaries, can totally suppress the action of natural killer T cells in the immune system.

Known as NKTs for short, these special T cells must be activated to do their job of jump-starting the immune response and signaling other kinds of white blood cells to rid the body of diseases or leave healthy tissue alone.

As part of the study, researchers collected lipid-filled ascites from 25 women with ovarian cancer and then exposed the lipid samples to an immune system test to see if they blocked activation of NKT cells.

In a report set to appear in the Dec.1 issue of the journal Clinical Cancer Research, the research team also found this evasive blocking tactic to be virtually exclusive to a specific protein, called CD1d, needed to activate the NKT cells.

Their experiments specifically showed that NKT activation was blocked between 10 percent and 100 percent after test cultures of cells that stimulate NKT cells were exposed to increasing concentrations of tumor-derived ascites.

Disrupted or stalled T cell action has been known to play a key role in the spread of several kinds of cancer, the scientists say. But until now, there was no firm evidence that tied a specific T cell in the body's defensive immune system to ovarian cancer.

"Our study findings lay out for the first time how ovarian cancer evades a critical check-point in the immune response, opening the door to future drug development that can halt, limit, reverse or even bypass the blockage, permitting CD1d-mediated NKT cell activation," says immunologist and study senior investigator Mathias Oelke, Ph.D.

According to Oelke, an assistant professor at Johns Hopkins, the research is believed to be the first to demonstrate the clinical effect of ascites on human NKT cells and describe the regulatory role of lipids in cancer progression. Previous studies in mice have confirmed that lipids assist in tumor evasion, he notes. But he says this is the first evidence in humans about the immune-suppressing effects of ascites on NKT cells, which are also abundant in cancers that spread to the abdomen and in other infectious diseases.

"The ultimate goal, of course, is to make sure the immune system can detect the cancer and, we hope, attack and eliminate it," says study co-investigator Jonathan Schneck, M.D., Ph.D. Schneck, a professor of pathology, medicine and oncology, described the blocking as "rapid and prolonged," happening within four hours of ascites exposure and remaining constant for the test duration.

When ascites extracted from men and women with another disease, hepatitis C, were exposed to cells that stimulate NKT cells, only two of six ascites samples blocked its activation.

And in another experiment, immune system CD8 "killer" T cells functioned normally, even when their stimulator cells were previously treated with ascites.

Moreover, the blocking action only occurred with ascites. Matching blood serum samples from the women with cancer failed to block NKT activation.

Researchers say their next steps are to evaluate more than a dozen varieties of lipids that exist in the body to determine their specific role, if any, in modulating the blocking of the NKT cell immune response. Their goal, researchers say, is to find links to other diseases and T-cell activity gone awry.


'/>"/>

Contact: David March
dmarch1@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Study shows how shift workers can improve job performance and implement a realistic sleep schedule
2. Study Recruiting From Alzheimers-Prone Families
3. Aged care workers to leave industry en masse due to stress, warns University of Melbourne study
4. Study compares strategies for BK virus nephropathy
5. Study: Childhood constipation just as serious as asthma
6. Stanford/Packard study shows no benefit from drug widely used to prevent premature births
7. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
8. Study: Want to be happier? Be more grateful
9. Study Calls for Greater Scrutiny of Off-Label Drug Use
10. Study suggests reliability of cognitive assessment tool varies widely
11. Study identifies double-balloon enteroscopy as cost-effective approach for obscure GI bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... planning services and products in the developing world, is pleased to release their ... prevent over 5 million unwanted pregnancies, almost 14,000 maternal deaths and 3.8 million ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Clearinghouse supporting the real time adjudication of medical service claims by Pharmacy Benefit ... their current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard ...
(Date:5/25/2016)... ... , ... The University of San Francisco (USF) has named Margaret Wooding Baker ... of more than 100 full-time faculty and staff, and serve as a member of ... , Baker comes to USF from the University of Washington in Seattle, where she ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & Wellness Center ... hands of time of female aging. The Juliet™ procedure helps to ... such as leakage, laxity, itchiness and pain have reported real relief from these and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Researchers from SUNY State ... Meeting for their work on visual evoked potential and human attention. The article, ... used the Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, Inc., ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... N.J. , May 24, 2016 ... oncology drug development company, today provided an update ... dose escalating clinical trial combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  GEN-1 is an IL-12 DNA ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology: